A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges

Journal of Virology

Volumn 87, Issue 14, 2013, Pages 7874-7881

  Uraki, Ryuta ^a   Kiso, Maki ^a   Iwatsuki Horimoto, Kiyoko ^a   Fukuyama, Satoshi ^b   Takashita, Emi ^c   Ozawa, Makoto ^d   Kawaokaa, Yoshihiro ^a,b,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, VIRAL; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; DOGS; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; KINETICS; MADIN DARBY CANINE KIDNEY CELLS; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PLASMIDS; RNA REPLICASE; VIRAL PROTEINS;

EID: 84880302696     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00076-13     Document Type: Article

References (30)

1. van der Wouden JC, Bueving HJ, Poole P. 2005. Preventing influenza: an overview of systematic reviews. Respir. Med. 99:1341-1349.
2. Nabel GJ, Fauci AS. 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16:1389-1391.
3. Lambert LC, Fauci AS. 2010. Influenza vaccines for the future. N. Engl. J. Med. 363:2036-2044.
4. Girard MP, Katz J, Pervikov Y, Palkonyay L, Kieny MP. 2010. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Vaccine 28:6811-6820.
5. Cox RJ, Brokstad KA, Ogra P. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59:1-15.
6. Rimmelzwaan GF, Fouchier RA, Osterhaus AD. 2007. Influenza virusspecific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18:529-536.
7. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.MMWRRecomm. Rep. 59:1-62.
8. Palese P, Garcia-Sastre A. 2002. Influenza vaccines: present and future. J. Clin. Invest. 110:9-13.
9. Khan AS, Polezhaev F, Vasiljeva R, Drinevsky V, Buffington J, Gary H, Sominina A, Keitel W, Regnery H, Lonskaya NL, Doroshenko E, Gavrilov A, Ivakhov I, Arden N, Schonberger LB, Couch R, Kendal A, Cox N. 1996. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J. Infect. Dis. 173:453-456.
10. Ozawa M, Victor ST, Taft AS, Yamada S, Li C, Hatta M, Das SC, Takashita E, Kakugawa S, Maher EA, Neumann G, Kawaoka Y. 2011. Replication-incompetent influenza A viruses that stably express a foreign gene. J. Gen. Virol. 92:2879-2888.
11. Victor ST, Watanabe S, Katsura H, Ozawa M, Kawaoka Y. 2012. A replication-incompetent PB2-knockout influenza A virus vaccine vector. J. Virol. 86:4123-4128.
12. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12:36-44.
13. Dolgin E. 2012. Four-strain flu vaccines coming to a pharmacy near you. Nat. Med. 18:471.
14. Schultz-Cherry S, Jones JC. 2010. Influenza vaccines: the good, the bad, and the eggs. Adv. Virus Res. 77:63-84.
15. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.
16. Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C, Mitamura K, Sugaya N, Suzuki Y, Kawaoka Y. 2005. Enhanced expression of an alpha2,6-linked sialic acid onMDCKcells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J. Clin. Microbiol. 43:4139-4146.
17. Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y. 2011. Mutations in PA, NP, andHAof a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res. 158:124-129.
18. Yamada S, Hatta M, Staker BL, Watanabe S, Imai M, Shinya K, Sakai-Tagawa Y, Ito M, Ozawa M, Watanabe T, Sakabe S, Li C, Kim JH, Myler PJ, Phan I, Raymond A, Smith E, Stacy R, Nidom CA, Lank SM, Wiseman RW, Bimber BN, O'connor DH, Neumann G, Stewart LJ, Kawaoka Y. 2010. Biological and structural characterization of a hostadapting amino acid in influenza virus. PLoS Pathog. 6:e1001034. doi:10.1371/journal.ppat.1001034.
19. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. U. S. A. 96:9345-9350.
20. Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, Iwatsuki-Horimoto K, Ito M, Tagawa-Sakai Y, Yamada S, Ito H, Ito T, Imai M, Itamura S, Odagiri T, Tashiro M, Lim W, Guan Y, Peiris M, Kawaoka Y. 2006. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24:3669-3676.
21. Murakami S, Horimoto T, Mai le, Nidom QCA, Chen H, Muramoto Y, Yamada S, Iwasa A, Iwatsuki-Horimoto K, Shimojima M, Iwata A, Kawaoka Y. 2008. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. J. Virol. 82:10502-10509.
22. Kida H, Brown LE, Webster RG. 1982. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology 122:38-47.
23. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025.
24. Benton KA, Misplon JA, Lo CY, Brutkiewicz RR, Prasad SA, Epstein SL. 2001. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J. Immunol. 166:7437-7445.
25. Clements ML, Betts RF, Tierney EL, Murphy BR. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24:157-160.
26. Renegar KB, Small PA, Jr. 1991. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 146:1972-1978.
27. Tumpey TM, Renshaw M, Clements JD, Katz JM. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150.
28. Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM. 2011. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6:e14538. doi:10.1371/journal.pone.0014538.
29. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC. 2011. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 52:1-7.
30. Hall CB. 2001. Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344:1917-1928.